acetylglucosamine has been researched along with calpain in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatham, JC; Liu, J; Marchase, RB | 1 |
| Cheng, Q; Ding, F; Li, L; Liu, M; Yang, Y; Yu, S | 1 |
| Balana, A; De Leon, CA; Galesic, A; Levine, PM; Lewis, YE; Marotta, NP; Pratt, MR | 1 |
3 other study(ies) available for acetylglucosamine and calpain
| Article | Year |
|---|---|
Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis.
Topics: Acetylglucosamine; Adenosine Triphosphate; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Calpain; Carrier Proteins; Glucosamine; Microfilament Proteins; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Oximes; Phenylcarbamates; Rats | 2007 |
2-(4-Methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside confers neuroprotection in cell and animal models of ischemic stroke through calpain1/PKA/CREB-mediated induction of neuronal glucose transporter 3.
Topics: Acetylglucosamine; Animals; Brain Ischemia; Calpain; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation; Glucose Transporter Type 3; Hippocampus; Mice; Molecular Structure; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Stroke | 2014 |
O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
Topics: Acetylglucosamine; alpha-Synuclein; Calpain; Escherichia coli; Humans; Parkinson Disease; Peptides; Protein Processing, Post-Translational; Proteolysis; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization | 2017 |